ArticleEuropean journal of anaesthesiology and intensive care2026
Successful treatment of refractory anaphylactic shock with angiotensin II: A case report.
Article in European journal of anaesthesiology and intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory anaphylaxis is a severe form of anaphylaxis, defined as anaphylaxis requiring ongoing treatment despite two appropriate doses of epinephrine. There is a lack of data about second-line vasopressor treatment in refractory anaphylaxis. We present a case report of refractory anaphylaxis after a young female received a gadolinium-based contrast medium and was successfully treated with an angiotensin II (ATII) infusion. ATII is converted from angiotensin I by the action of the angiotensin-converting enzyme (ACE). Since oestrogen has an inhibitory effect upon mRNA synthesis of ACE, premenopausal women have lower ACE and ATII levels, making them more prone to anaphylaxis. There are also gene polymorphisms related to lower ATII levels in patients with severe anaphylaxis. Since ATII has no effect on mastocytes and bronchospasm, it can only be used as a second-line vasopressor beside epinephrine and fluid treatment in refractory anaphylaxis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.